{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:21:02Z","timestamp":1794370862273,"version":"4.9.0"},"edition-number":"1","reference-count":26,"publisher":"Cambridge University Press","isbn-type":[{"value":"9780521515030","type":"print"},{"value":"9780511551901","type":"electronic"}],"license":[{"start":{"date-parts":[[2009,7,11]],"date-time":"2009-07-11T00:00:00Z","timestamp":1247270400000},"content-version":"unspecified","delay-in-days":257,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10,27]]},"DOI":"10.1017\/cbo9780511551901.004","type":"book-chapter","created":{"date-parts":[[2009,12,24]],"date-time":"2009-12-24T09:31:08Z","timestamp":1261647068000},"page":"37-45","source":"Crossref","is-referenced-by-count":0,"title":["MAINTENANCE THERAPY IN MULTIPLE MYELOMA"],"prefix":"10.1017","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","reference":[{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib207","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib226","first-page":"58","article-title":"Prosser IW. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6)","volume":"108","author":"Spencer","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib216","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib223","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib217","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06405.x"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib221","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06817.x"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib222","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21852"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib220","article-title":"Thalidomide maintenance following high dose therapy in multiple myeloma: A UK Myeloma Forum Phase 2 Study","volume":"102","author":"Feyler","year":"2003","journal-title":"Blood"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib224","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101212"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib208","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.8.453"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib210","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.171"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib212","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib225","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib219","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1106"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib209","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840201)53:3<583::AID-CNCR2820530336>3.0.CO;2-1"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib214","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026548226770"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib206","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma","volume":"135","author":"Alexanian","year":"1975","journal-title":"Arch Intern Med"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib231","first-page":"3535","article-title":"Analysis of varicella zoster virus reactivation among bortezomib-treated patients in the APEX study","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib228","first-page":"3237","article-title":"Bortezomib (velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)","volume":"106","author":"Peles","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib215","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib211","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.888"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib229","first-page":"5433","article-title":"Phase I\/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma","volume":"108","author":"Schiller","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib213","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib218","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf188"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib227","first-page":"41","article-title":"Prosser I. Thalidomide improves survival when used following ASCT","volume":"92","author":"Spencer","year":"2007","journal-title":"Haematologica"},{"key":"9780511551901.CBO9780511551901A010_CBO9780511551901bib230","first-page":"5099","article-title":"Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma","volume":"108","author":"Knop","year":"2006","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Treatment of Multiple Myeloma and Related Disorders"],"original-title":[],"link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/D393A42616AA83386A9A7739A914C96B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T10:59:45Z","timestamp":1655117985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/CBO9780511551901A010\/type\/book_part"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,27]]},"ISBN":["9780521515030","9780511551901"],"references-count":26,"URL":"https:\/\/doi.org\/10.1017\/cbo9780511551901.004","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1017\/cbo9780511551901","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,10,27]]}}}